Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-10,162
Closed -$7.66K 3182
2023
Q3
$7.66K Buy
+10,162
New +$7.73K ﹤0.01% 2881
2023
Q1
Sell
-231,204
Closed -$222K 2885
2022
Q4
$222K Buy
231,204
+341
+0.1% +$482 ﹤0.01% 2270
2022
Q3
$503K Sell
230,863
-10,712
-4% -$36.9K ﹤0.01% 1416
2022
Q2
$846K Sell
241,575
-9,180
-4% -$34.3K ﹤0.01% 962
2022
Q1
$1.26M Buy
250,755
+100,343
+67% +$508K ﹤0.01% 861
2021
Q4
$943K Buy
150,412
+168
+0.1% +$1.15K ﹤0.01% 842
2021
Q3
$1.19M Buy
150,244
+31
+0% +$255 0.01% 657
2021
Q2
$1.13M Buy
150,213
+213
+0.1% +$1.49K 0.01% 637
2021
Q1
$908K Buy
150,000
+39,908
+36% +$307K 0.01% 630
2020
Q4
$629K Buy
+110,092
New +$700K ﹤0.01% 643

Other funds holding VXRT

Mariner's VXRT Position: Q4 2023 in Review

Mariner sold out of Vaxart (VXRT) in Q4 2023, closing a stake of 10,162 shares — an estimated $7.66K sold.

Mariner first reported a position in VXRT in Q4 2020 and held it in 10 quarters. The position peaked at $1.26M in Q1 2022. 87 funds tracked by Wall St. Rank hold VXRT as of Q4 2023.

  • Mariner reported no remaining Vaxart position as of Q4 2023 after selling out during the quarter.
  • Mariner sold 10,162 Vaxart shares in Q4 2023, an estimated $7.66K.
  • Mariner first reported a position in Vaxart in Q4 2020 and held it in 10 quarters.
  • Mariner's Vaxart position peaked at $1.26M in Q1 2022.
  • 87 funds tracked by Wall St. Rank held Vaxart as of Q4 2023.

Based on Mariner's 13F filing for Q4 2023, filed 14 Feb 2024.